New BOBP ETF Targets US Large-Caps Using CORE16's Proprietary Skewness Model
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2025
0mins
Should l Buy KVUE?
Source: Benzinga
New ETF Launch: Exchange Traded Concepts has launched the CORE16 Best of Breed Premier Index ETF (BOBP), which aims to capitalize on market opportunities through a dynamic rebalancing strategy based on equity skewness, allowing for tactical investment decisions.
Investment Strategy: The fund utilizes a proprietary algorithm to select 50 large-cap U.S. securities, focusing on stocks with favorable performance asymmetries, and represents ETC's expansion into niche ETFs in the U.S. market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 17.260
Low
17.00
Averages
18.86
High
23.00
Current: 17.260
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Johnson & Johnson vs. Pfizer: The Future of Healthcare Stocks
- Successful Spin-off: Johnson & Johnson's spin-off of its slow-growing consumer health division into Kenvue in 2023 has led to enhanced operational efficiency, with revenue reaching $88.8 billion in 2024 and projected to grow to between $99.5 billion and $100.5 billion by 2026, indicating strong growth potential in the healthcare market.
- Pfizer's Revenue Challenges: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; despite efforts to strengthen its oncology pipeline through acquisitions like Seagen and Metsera, revenue is expected to remain flat in 2026, ranging from $59.5 billion to $62.5 billion, highlighting growth risks.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; although Pfizer appears undervalued with a lower forward P/E ratio, its lower future earnings expectations may signal risks, whereas Johnson & Johnson's 60+ years of consistent dividend growth suggests greater sustainability.
- Market Outlook Analysis: Amid concerns over inflation, AI bubbles, and geopolitical risks, Johnson & Johnson's broad product portfolio, steady cash flow, and reliable dividend payments position it as a focal point for investors seeking potential shareholder returns over the next decade.
See More
Market Performance Analysis of Johnson & Johnson and Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and an expected range of $99.5 billion to $100.5 billion for 2026, indicating a clearer business focus and enhanced growth following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; while its drug development efforts, particularly in oncology and the acquisition of Seagen, suggest future growth potential, the short-term revenue stability remains a concern.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, compared to Johnson & Johnson's 2.1%; although Pfizer's yield appears more attractive, Johnson & Johnson's consistent dividend increases over the past 60 years reflect its financial stability and sustainability.
- Market Outlook Assessment: In the current economic climate, Johnson & Johnson demonstrates higher growth potential due to its diverse product portfolio and steady cash flow, leading analysts to favor its future earnings capability, making it a suitable focus for long-term investors.
See More
Investment Opportunities in Consumer Staples Stocks
- Dividend Durability: Despite short-term earnings pressure, General Mills (GIS) maintains a 127-year uninterrupted dividend payment history, currently yielding 6.7%, making it highly attractive for long-term income investors within the S&P 500.
- Brand Resilience: Hormel Foods (HRL) has raised its dividend for 59 consecutive years, and despite a 50% drop in share price since April 2022, its brands like Spam and Skippy remain market leaders, showcasing strong brand resilience and adaptability.
- Market Potential: Kenvue (KVUE), spun off from Johnson & Johnson in 2023, has seen its stock price drop about 30%, yet its product portfolio including Tylenol and Listerine shows a 3.2% revenue growth quarter-over-quarter, indicating defensibility and growth potential in consumer health.
- E-commerce Penetration: Church & Dwight (CHD) has achieved a 23% e-commerce channel share in global sales, with brands like Arm & Hammer contributing 70% of revenue, and is guiding for 3% to 4% organic sales growth in 2026, highlighting strong market prospects and investment value.
See More
Investment Opportunities in Consumer Stocks
- Market Confidence Decline: The consumer confidence index has dropped to 56.4, nearing recession levels, prompting a shift towards defensive businesses, and despite flat performance in consumer staples in 2025, there are opportunities to buy at low prices.
- General Mills' Investment Value: General Mills (GIS) is trading at a 15-year low with a year-to-date decline of about 21%, yet its 127-year uninterrupted dividend history and a 6.7% yield make it a reliable choice for long-term passive income.
- Hormel Foods' Resilience: Hormel Foods (HRL) has raised its dividend for 59 consecutive years, and despite a 50% drop from its 2022 peak, its brand leadership and dual position in private-label manufacturing provide a defensive edge.
- Kenvue's Market Potential: Kenvue (KVUE), spun off from Johnson & Johnson, is down 30% from its 52-week high, but its stable product portfolio and analyst support make it an investment worth considering.
See More
Johnson & Johnson: Strong Dividend Record and Diversified Business
- Dividend King Status: Johnson & Johnson (JNJ) boasts a remarkable 63-year streak of dividend increases, far surpassing the 54-year records of the other four healthcare Dividend Kings, showcasing its exceptional ability to provide stable income.
- Business Diversification: As one of the world's largest pharmaceutical companies, J&J not only holds a significant position in the drug sector but also benefits from its medical device business, which offers reliable cash flows that mitigate the risks associated with drug patent expirations.
- Future Plans: J&J plans to spin off its orthopedics business in 2027, focusing its medical device operations on cardiovascular, surgical, and vision sectors, which will further streamline its business and ensure continued revenue growth from its drug division.
- Credit Rating Advantage: With an AAA credit rating, J&J demonstrates solid financial health; although its dividend yield is around 2.2%, lower than the 4% target for many investors, its stability and reliability make it an attractive option in the pharmaceutical sector.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Johnson & Johnson vs. Pfizer: The Future of Healthcare Stocks
- Successful Spin-off: Johnson & Johnson's spin-off of its slow-growing consumer health division into Kenvue in 2023 has led to enhanced operational efficiency, with revenue reaching $88.8 billion in 2024 and projected to grow to between $99.5 billion and $100.5 billion by 2026, indicating strong growth potential in the healthcare market.
- Pfizer's Revenue Challenges: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; despite efforts to strengthen its oncology pipeline through acquisitions like Seagen and Metsera, revenue is expected to remain flat in 2026, ranging from $59.5 billion to $62.5 billion, highlighting growth risks.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; although Pfizer appears undervalued with a lower forward P/E ratio, its lower future earnings expectations may signal risks, whereas Johnson & Johnson's 60+ years of consistent dividend growth suggests greater sustainability.
- Market Outlook Analysis: Amid concerns over inflation, AI bubbles, and geopolitical risks, Johnson & Johnson's broad product portfolio, steady cash flow, and reliable dividend payments position it as a focal point for investors seeking potential shareholder returns over the next decade.
See More
Market Performance Analysis of Johnson & Johnson and Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and an expected range of $99.5 billion to $100.5 billion for 2026, indicating a clearer business focus and enhanced growth following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; while its drug development efforts, particularly in oncology and the acquisition of Seagen, suggest future growth potential, the short-term revenue stability remains a concern.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, compared to Johnson & Johnson's 2.1%; although Pfizer's yield appears more attractive, Johnson & Johnson's consistent dividend increases over the past 60 years reflect its financial stability and sustainability.
- Market Outlook Assessment: In the current economic climate, Johnson & Johnson demonstrates higher growth potential due to its diverse product portfolio and steady cash flow, leading analysts to favor its future earnings capability, making it a suitable focus for long-term investors.
See More
Investment Opportunities in Consumer Staples Stocks
- Dividend Durability: Despite short-term earnings pressure, General Mills (GIS) maintains a 127-year uninterrupted dividend payment history, currently yielding 6.7%, making it highly attractive for long-term income investors within the S&P 500.
- Brand Resilience: Hormel Foods (HRL) has raised its dividend for 59 consecutive years, and despite a 50% drop in share price since April 2022, its brands like Spam and Skippy remain market leaders, showcasing strong brand resilience and adaptability.
- Market Potential: Kenvue (KVUE), spun off from Johnson & Johnson in 2023, has seen its stock price drop about 30%, yet its product portfolio including Tylenol and Listerine shows a 3.2% revenue growth quarter-over-quarter, indicating defensibility and growth potential in consumer health.
- E-commerce Penetration: Church & Dwight (CHD) has achieved a 23% e-commerce channel share in global sales, with brands like Arm & Hammer contributing 70% of revenue, and is guiding for 3% to 4% organic sales growth in 2026, highlighting strong market prospects and investment value.
See More
Investment Opportunities in Consumer Stocks
- Market Confidence Decline: The consumer confidence index has dropped to 56.4, nearing recession levels, prompting a shift towards defensive businesses, and despite flat performance in consumer staples in 2025, there are opportunities to buy at low prices.
- General Mills' Investment Value: General Mills (GIS) is trading at a 15-year low with a year-to-date decline of about 21%, yet its 127-year uninterrupted dividend history and a 6.7% yield make it a reliable choice for long-term passive income.
- Hormel Foods' Resilience: Hormel Foods (HRL) has raised its dividend for 59 consecutive years, and despite a 50% drop from its 2022 peak, its brand leadership and dual position in private-label manufacturing provide a defensive edge.
- Kenvue's Market Potential: Kenvue (KVUE), spun off from Johnson & Johnson, is down 30% from its 52-week high, but its stable product portfolio and analyst support make it an investment worth considering.
See More
Johnson & Johnson: Strong Dividend Record and Diversified Business
- Dividend King Status: Johnson & Johnson (JNJ) boasts a remarkable 63-year streak of dividend increases, far surpassing the 54-year records of the other four healthcare Dividend Kings, showcasing its exceptional ability to provide stable income.
- Business Diversification: As one of the world's largest pharmaceutical companies, J&J not only holds a significant position in the drug sector but also benefits from its medical device business, which offers reliable cash flows that mitigate the risks associated with drug patent expirations.
- Future Plans: J&J plans to spin off its orthopedics business in 2027, focusing its medical device operations on cardiovascular, surgical, and vision sectors, which will further streamline its business and ensure continued revenue growth from its drug division.
- Credit Rating Advantage: With an AAA credit rating, J&J demonstrates solid financial health; although its dividend yield is around 2.2%, lower than the 4% target for many investors, its stability and reliability make it an attractive option in the pharmaceutical sector.
See More
